Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Actuate Therapeutics IncNASDAQ: ACTU
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity turns positive
Q1 FY2026 total equity was $3.78M, compared with -$5.09M a year earlier. Over 3 fiscal years it compounded at -18.9% a year.
Context
- Total equity amounted to 42.5% of total assets at the end of Q1 FY2026, down 71.0 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +174.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 7.92M USD
- Year-over-year change
- +7505.6%
- 3-year CAGR
- -18.9%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.92M | +7505.6% |
| FY2024 | 2024-12-31 | 104.19K | +100.1% |
| FY2023 | 2023-12-31 | (99.63M) | -771.7% |
| FY2022 | 2022-12-31 | 14.83M | — |
Total Equity vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +174.4% is the highest of 9, against a peer median of -47.1%.
- Total equity amounts to 42.5% of total assets for ACTU, versus a peer median of 53.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $285.86M USD | -24.5% | -5.7% | 76.8% | |
| Mar 2026 | $133.98M USD | +45.9% | -6.4% | 85.7% | |
| Mar 2026 | CHF 68.25M CHF | -46.8% | -30.1% | 78.1% | |
| Mar 2026 | $52.93M USD | +56.5% | -8.1% | 89.7% | |
| Mar 2026 | $26.5M USD | -47.5% | +60.1% | 22.5% | |
| Mar 2026 | $10.38M USD | -89.0% | -47.7% | 4.3% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $3.78M USD | +174.4% | -18.9% | 42.5% |
ELTXElicio Therapeutics, Inc. | Mar 2026 | -$1.44M USD | -116.1% | -43.2% | 6.3% |
| Mar 2026 | -$150.42M USD | -327.7% | — | 29.7% | |
| Peer median (excluding ACTU) | — | -47.1% | -8.1% | 53.3% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.